Search hospitals > Nebraska > Omaha
Alegent Health Bergan Mercy Medical Center
Claim this profileOmaha, Nebraska 68124
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Lung Cancer
Conducts research for Adenocarcinoma
Conducts research for Recurrence
279 reported clinical trials
8 medical researchers
Summary
Alegent Health Bergan Mercy Medical Center is a medical facility located in Omaha, Nebraska. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Adenocarcinoma, Recurrence and other specialties. Alegent Health Bergan Mercy Medical Center is involved with conducting 279 clinical trials across 534 conditions. There are 8 research doctors associated with this hospital, such as Richard L. Deming, Shahzad Siddique, Mehmet S. Copur, and Lee Morrow, MD.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage II
2Breast Cancer
Global LeaderStage IV
HER2 negative
ER positive
Top PIs
Richard L. DemingMercy Medical Center - Des Moines4 years of reported clinical research
Expert in Cancer
Expert in Breast Cancer
172 reported clinical trials
239 drugs studied
Shahzad SiddiquePenrose-Saint Francis Healthcare4 years of reported clinical research
Expert in Cancer
Expert in Breast Cancer
111 reported clinical trials
176 drugs studied
Mehmet S. CopurBethesda North Hospital12 years of reported clinical research
Studies Breast Cancer
Studies Ovarian Cancer
2 reported clinical trials
8 drugs studied
Lee Morrow, MDCreighton University Clinical Research Office3 years of reported clinical research
Studies Pulmonary Fibrosis
Studies Fibrosis
2 reported clinical trials
4 drugs studied
Clinical Trials running at Alegent Health Bergan Mercy Medical Center
Breast Cancer
Lung Cancer
Cancer
Non-Small Cell Lung Cancer
Bladder Cancer
Bladder Carcinoma
Squamous Cell Carcinoma
Gastric Cancer
Prostate Cancer
Pancreatic Cancer
Carvedilol
for Preventing Heart Problems in HER2 Positive Breast Cancer
This phase III trial studies how well carvedilol works in preventing cardiac toxicity in patients with human epidermal growth factor receptor (HER)-2-positive breast cancer that has spread to other places in the body. A beta-blocker, such as carvedilol, is used to treat heart failure and high blood pressure, and it may prevent the heart from side effects of chemotherapy.
Recruiting2 awards Phase 323 criteria
Shorter Chemo-Immunotherapy Without Anthracyclines
for Breast Cancer
This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medications called anti-microtubule agents. It stops cancer cells from growing and dividing and may kill them. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid (DNA) and may kill cancer cells. It may also lower the body's immune response. Docetaxel is in a class of medications called taxanes. It stops cancer cells from growing and dividing and may kill them. Doxorubicin is an anthracycline chemotherapy drug that damages DNA and may kill cancer cells. Pembrolizumab may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Shorter treatment without anthracycline chemotherapy may work the same as the usual anthracycline chemotherapy treatment for early-stage triple negative breast cancer.
Recruiting2 awards Phase 347 criteria
Omitting Radiation Therapy
for Breast Cancer
The purpose of this study is to compare the effects on low risk breast cancer receiving usual care that includes regional radiation therapy, with receiving no regional radiation therapy. Researchers want to see if not giving this type of radiation treatment works as well at preventing breast cancer from coming back.
Recruiting2 awards Phase 319 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Alegent Health Bergan Mercy Medical Center?
Alegent Health Bergan Mercy Medical Center is a medical facility located in Omaha, Nebraska. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Adenocarcinoma, Recurrence and other specialties. Alegent Health Bergan Mercy Medical Center is involved with conducting 279 clinical trials across 534 conditions. There are 8 research doctors associated with this hospital, such as Richard L. Deming, Shahzad Siddique, Mehmet S. Copur, and Lee Morrow, MD.